Gilead (GILD) reports Q1 revenue $5.55B, consensus $5.45B. "Gilead's performance during the first quarter demonstrates our continued progress and highlights the strength of our underlying business. While we are prepared to navigate the uncertainty and short-term impact from the pandemic, we are confident in our ability to deliver on our long-term goals," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. "Our focus at this time is on both our work with remdesivir and our ongoing commitments to the people who depend on our medicines today."

Total product sales for the first quarter of 2020 were $5.5 billion compared to $5.2 billion for the same period in 2019. Product sales for the first quarter of 2020 were $4.0 billion in the United States, $927 million in Europe and $551 million in other locations. Product sales for the first quarter of 2019 were $3.8 billion in the United States, $882 million in Europe and $522 million in other locations. Total product sales for the first quarter 2020 benefited from an estimated $200 million in revenue related to increased customer buying patterns and patient prescription trends, primarily in the United States, due to the coronavirus disease (COVID-19) pandemic.